Ablynx

Ablynx (EBR:ABLX) GHENT, Belgium, 20 January, 2009 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, has expanded its musculoskeletal research portfolio by transferring in-house full ownership of a bone disorder R&D programme initiated under its collaboration with Procter & Gamble Pharmaceuticals.

Ablynx (EBR:ABLX) * Pulmonary delivery of anti-viral Nanobodies® gives extended protection against viral infection in vivo * In vivo proof of concept for its novel proprietary half-life extension technology

Ablynx (EBR:ABLX) ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 27TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Ablynx (EBR:ABLX) GHENT, Belgium, 8 January 2009 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that it has appointed Dr Debbie Law, as its Chief Scientific Officer.

Ablynx (EBR:ABLX) GHENT, Belgium, 12 December 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that its anti-thrombotic ALX-0081, has reached the primary endpoint of the current Phase Ib study, demonstrating the desired pharmacological effect.

Ablynx (EBR:ABLX) Ghent, Belgium, 10 December 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, today announced that it has reached a milestone under the terms of its collaboration with Wyeth Pharmaceuticals, a division of Wyeth. A milestone payment of $3 million has been triggered by the initiation by Wyeth of a first Phase I study in healthy volunteers for a Nanobody® targeting tumour necrosis factor alpha (TNF-alpha).

Ablynx (EBR:ABLX) GHENT, Belgium, 8 December 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that it has initiated a double-blind, randomized, placebo-controlled Phase I study in healthy volunteers with ALX-0681. The subjects will receive a subcutaneous injection of the novel anti-thrombotic Nanobody® that selectively targets von Willebrand (vWF) factor.

Ablynx (EBR:ABLX) REGULATED INFORMATION

Ablynx (EBR:ABLX) Publication of transparency notifications in accordance with Article 14 of the Belgian Act of 2 May 2007 regarding the publication of major shareholdings

Ablynx (EBR:ABLX) GHENT, Belgium, 20 October, 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that a consortium, comprising DG Infra+, B.S.I. and Foremost Immo, has committed to invest in the development of a 10,000 m² cutting-edge laboratory facility (the Bio-Accelerator) on the Technologiepark in Zwijnaarde, Ghent. This facility will be close to Ablynx's existing facilities and the company has secured the right to use 70% of the capacity of the Bio-Accelerator, which is expected to be completed by mid-2010.